Arcus (RCUS) falls 2.57% on Strong Volume September 14

Equities Staff  |

Arcus Biosciences Inc (NYSE: RCUS) shares fell 2.57%, or $0.87 per share, to close Tuesday at $33.01. After opening the day at $33.52, shares of Arcus fluctuated between $33.83 and $32.38. 464,915 shares traded hands an increase from their 30 day average of 364,035. Tuesday's activity brought Arcus’s market cap to $2,356,717,161.

About Arcus Biosciences Inc

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.

Visit Arcus Biosciences Inc’s profile for more information.

About The New York Stock Exchange

The New York Stock Exchange is the world’s largest stock exchange by market value at over $26 trillion. It is also the leader for initial public offerings, with $82 billion raised in 2020, including six of the seven largest technology deals. 63% of SPAC proceeds in 2020 were raised on the NYSE, including the six largest transactions.

To get more information on Arcus Biosciences Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Arcus Biosciences Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

FAA Urges Airlines To Take Stronger Action With Unruly, Disruptive Passengers
Freshworks Leaps 32% on First Day of Trading After Pricing Above Filing Range
Twitter Settles Class Action for $809.5 Million Over Providing Misleading Information to Investors
DoorDash Adds Alcohol Delivery in 20 US States, DC, Canada, Australia
Bill Gates Raises More Than $1 Billion for Clean Energy Technology
CVS Health To Hire 25,000 in Virtual Career Event Friday September 24
President Biden's New Alliance With Australia and Britain Angers France and European Union
California Governor Newsom Signs Affordable Housing Law



Market Movers

Sponsored Financial Content